Emerging research suggest this peptide, a dual stimulator targeting both the gut-brain axis and another hormone, could represent a notable step forward for obesity management . Initial patient tests have shown substantial losses in visceral tissue, conceivably outperforming current obesity therapies . Despite this, further assessment is required to